Myocardial myostatin in spontaneously hypertensive rats with heart failure

R L Damatto1, A R R Lima1, P F Martinez2

  • 1Department of Internal Medicine, Botucatu Medical School, Sao Paulo State University, UNESP, Brazil.

Insights

Myostatin and follistatin protein expression decreases in the hearts of spontaneously hypertensive rats with heart failure. This reduction correlates with cardiac dysfunction and hypertrophy, suggesting a role in disease progression.

Area of Science:

  • Cardiology
  • Molecular Biology
  • Physiology

Background:

  • Myostatin regulates skeletal and cardiac muscle growth.
  • Its role in long-term myocardial hypertrophy and heart failure is not well understood.

Purpose of the Study:

  • To investigate myocardial myostatin and follistatin expression in spontaneously hypertensive rats (SHR) with heart failure.

Main Methods:

  • Evaluated 18-month-old SHR for heart failure signs.
  • Conducted echocardiography and Western blotting for protein expression.
  • Used age-matched Wistar-Kyoto (WKY) rats as controls.

Main Results:

  • SHR exhibited right ventricular hypertrophy, lung congestion, and left chamber dilation/hypertrophy.
  • Left ventricular systolic dysfunction, increased myocyte diameter, and collagen fraction were observed in SHR.
  • Both myostatin and follistatin expression were significantly lower in SHR compared to WKY rats.

Conclusions:

  • Reduced myostatin and follistatin protein expression occurs in the hypertrophied myocardium of SHR with heart failure.
  • These reductions correlate with cardiac dysfunction, indicating a potential role in the pathogenesis of heart failure.
Abstract

Related Concept Videos

Heart Failure II: Pathophysiology01:29

Heart Failure II: Pathophysiology

Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
1.3K
Cardiomyopathy III: Hypertrophic Cardiomyopathy01:29

Cardiomyopathy III: Hypertrophic Cardiomyopathy

Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
643
Pathophysiology of Heart Failure01:17

Pathophysiology of Heart Failure

Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
4.5K
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
1.4K